Core Points - The European Medicine Agency (EMA) has approved the extension of the shelf-life of AB Science's veterinary medicine MASIVET® from 36 months to 48 months [1] - MASIVET® is approved for treating non-resectable dog mast cell tumors (Grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor and is available in all EU countries [2] - The shelf-life extension provides flexibility for patients, caregivers, and AB Science in managing inventory levels, reducing the risk of product expiration, and ensuring continuity of therapies [3] Company Overview - AB Science, founded in 2001, specializes in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [4] - The company's lead compound, masitinib, is registered for veterinary medicine and is also being developed for human medicine in various fields including oncology and neurological diseases [5]